Quick Answer
VYNE Therapeutics Inc. reported Stockholders Equity of $27.77 million for fiscal year 2025.
VYNE Therapeutics Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $27.77M | -46.7% |
| 2024 | $52.09M | -41.3% |
| 2023 | $88.73M | +184.4% |
| 2022 | $31.20M | -35.8% |
| 2021 | $48.64M | +29.7% |
| 2020 | $37.49M | +113.3% |
| 2019 | $17.57M | -80.9% |
| 2018 | $92.18M | +34.4% |
| 2017 | $68.60M | +333.0% |
| 2016 | -$29.44M | -84.5% |
| 2015 | -$15.95M | -39.8% |
| 2014 | -$11.41M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| June 30, 2025 | $38.88M | -48.1% | -11.9% |
| March 31, 2025 | $44.13M | -47.1% | -15.3% |
| December 31, 2024 | $52.09M | -41.3% | -18.0% |
| September 30, 2024 | $63.54M | +452.3% | -15.1% |
| June 30, 2024 | $74.87M | +333.5% | -10.2% |
| March 31, 2024 | $83.37M | +215.4% | -6.0% |
| December 31, 2023 | $88.73M | +184.4% | +671.3% |
| September 30, 2023 | $11.51M | -71.3% | -33.4% |
- VYNE Therapeutics Inc. showed a decrease of -46.7% in Stockholders Equity compared to the prior fiscal year.
- Over the 2014–2025 period, VYNE Therapeutics Inc.’s stockholders equity has grown by 343.3% (from -$11.41 million to $27.77 million).
- The most recent figure is from VYNE Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: